TRAC is ideal for pre-clinical drug studies, as it allows the ADME-Tox profile of a drug to be investigated in many hundreds of samples, without sacrificing the number of genes being analysed. TRAC is also cost-effective and fast, allowing screening to be carried out very efficiently. Using gene expression to assess ADME-Tox response is especially powerful, as indicated in a recent draft report by the FDA, which recommended its suitability over protein-based methods.
We offer a range of pre-validated TRAC panels for ADME-Tox research in a range of model systems, including rat, humans and dogs. You can:
Over 6 reference genes and many targets to choose from, including:
Dedicated Human ADME-Tox services using our panels of pre-validated ADME-Tox probes:
More than 120 targets and over 14 reference genes to choose from, including:
A panel of the most common CYP 450 genes and reference genes for primary hepatocyte induction studies – Learn more